Drugs / Oglemilast
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials | ||||||
| Phase 2 | NCT00859404 | Oct 2008 → Dec 2009 | asthma | Glenmark Pharmaceuticals Europe Ltd. (R&D) | Unknown | No outcome recorded |
| Phase 2 | NCT00322686 | May → Dec 2006 | asthma | Forest Laboratories | Completed | No outcome recorded |
| Phase 2 | NCT00322283 | May → Oct 2006 | exercise-induced bronchoconstriction | Forest Laboratories | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00671073 Comparator | May 2008 → May 2009 | chronic obstructive pulmonary disease | Forest Laboratories | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | oglemilast | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00859404 ↗ |
| Known as | GRC 3845 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297520 ↗ |
| Modality | Small molecule | — CHEMBL4297520 ↗ |
| Route | Oral | “oral administration” NCT00322283 ↗ |